Description

Tirzepatide hydrochloride (LY3298176 hydrochloride) is a glucose-dependent insulin nutritive polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor dual agonist. Tirzepatide hydrochloride has neuroprotective effects and can be used in the study of type 2 diabetes, diabetes-related neuropathy and obesity[1][2][3].–80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)–Metabolism-sugar/lipid metabolism–C225H348N48O68.xHCl—bioRxiv. 2023 Dec 7.|J Am Chem Soc. 2023 Dec 13.|iScience. 2024 Feb 27.-[1]Fontanella RA, et al. Tirzepatide prevents neurodegeneration through multiple molecular pathways. J Transl Med. 2024 Jan 29;22(1):114.|[2]Huang L, et al. Tirzepatide inhibits tumor growth in mice with diet-induced obesity. bioRxiv, 2023: 2023.06. 22.546093.|[3]Guo X, et al. Tirzepatide ameliorates spatial learning and memory impairment through modulation of aberrant insulin resistance and inflammation response in diabetic rats. Front Pharmacol. 2023 Aug 28;14:1146960.—-4813.45 (free base)–99.82–OC[C@H](NC([C@H]1N(CCC1)C([C@H]2N(CCC2)C([C@H]3N(CCC3)C([C@@H](NC(CNC([C@@H](NC([C@@H](NC([C@H]4N(CCC4)C(CNC(CNC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC(C(C)(NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC(CNC([C@@H](NC(C(C)(NC([C@@H](N)CC5=CC=C(C=C5)O)=O)C)=O)CCC(O)=O)=O)=O)[C@@H](C)O)=O)CC6=CC=CC=C6)=O)[C@@H](C)O)=O)CO)=O)CC(O)=O)=O)CC7=CC=C(C=C7)O)=O)CO)=O)[C@H](CC)C)=O)C)=O)CC(C)C)=O)CC(O)=O)=O)CCCCN)=O)[C@H](CC)C)=O)C)=O)CCC(N)=O)=O)CCCCNC(COCCOCCNC(COCCOCCNC(CC[C@H](NC(CCCCCCCCCCCCCCCCCCC(O)=O)=O)C(O)=O)=O)=O)=O)=O)C)=O)CC8=CC=CC=C8)=O)C(C)C)=O)CCC(N)=O)=O)CC9=CNC=C9C=CC=C)=O)CC(C)C)=O)[C@H](CC)C)=O)C)=O)=O)=O)=O)CO)=O)CO)=O)=O)C)=O)=O)=O)=O)C(N)=O.[H]Cl.[x]–Cancer; Metabolic Disease; Neurological Disease–DMSO : 50 mg/mL (ultrasonic)–GLP Receptor—-GPCR/G Protein–Peptides